Anthony SJ, Epstein JH, Murray KA, Navarrete-Macias I, Zambrana-Torrelio CM, Solovyov A, Ojeda-Flores R, Arrigo NC, Islam A, Ali Khan S, Hosseini P, Bogich TL, Olival KJ, Sanchez-Leon MD, Karesh WB, Goldstein T, Luby SP, Morse SS, Mazet JA, Daszak P, Lipkin WI. A strategy to estimate unknown viral diversity in mammals. MBio. 2013;4(5):e00598–e00613. [PMC free article: PMC3760253] [PubMed: 24003179]

Butler D. How to beat the next Ebola. Nature. 2015;(524):22–25. [PubMed: 26245563]

Gates B. The next epidemic: Lessons from Ebola. New England Journal of Medicine. 2015;372:1381–1384. [PubMed: 25853741]

Ge XY, Lin JL, Yang XL, Chmura AA, Zhu G, Epstein JH. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;(503):535–538. http://dx​.doi.org/10.1038/nature12711. [PMC free article: PMC5389864] [PubMed: 24172901]

Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ, Kanneh L, Jalloh S, Momoh M, Fullah M, Dudas G, Wohl S, Moses LM, Yozwiak NL, Winnicki S, Matranga SB, Malboeuf CM, Qu J, Gladden AD, Schaffner SF, Yang X, Jiang PP, Nekoui M, Colubri A, Coomber MR, Fonnie M, Moigboi A, Gbakie M, Kamara FK, Tucker V, Konuwa E, Saffa S, Sellu J, Jalloh AA, Kovoma A, Koninga J, Mustapha I, Kargbo K, Foday M, Yillah M, Kanneh F, Robert W, Massally JL, Chapman SB, Bochicchio J, Murphy C, Nusbaum C, Young S, Birren BW, Grant DS, Scheiffelin JS, Lander ES, Happi C, Gevao SM, Gnirke A, Rambaut A, Garry RF, Khan SH, Sabeti PC. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014;345(6202):1369–1372. [PMC free article: PMC4431643] [PubMed: 25214632]

Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. Global trends in emerging infectious diseases. Nature. 2008;451(7181):990–993. [PMC free article: PMC5960580] [PubMed: 18288193]

Kinch MS, Patridge E, Plummer M, Hoyer D. An analysis of FDA-approved drugs for infectious disease: Antibacterial agents. Drug Discovery Today. 2014;19(9):1283–1287. [PubMed: 25043770]

Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H, Zhang J, McEachern J, Field H, Daszak P, Eaton BT, Zhang S, Wang LF. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005;310(5748):676–679. [PubMed: 16195424]

Matheny J, Mair M, Mulcahy A, Smith BT. Incentives for Biodefense Countermeasure Development. Biosecurity and Bioterrorism: Biodefense Strategy, Practice and Science. 2007;5:228–238. [PubMed: 17903091]

Maurice J. Too many unknowns stymie response to MERS. World Report. Lancet. 2015 [July 29, 2015]; http://www​.thelancet​.com/pdfs/journals/lancet​/PIIS0140-6736(15)61186-2.pdf. [PMC free article: PMC7137836] [PubMed: 26169850]

Memish ZA, Mishra N, Olival KJ, Fagbo SF, Kapoor V, Epstein JH, Alhakeem R, Durosinloun A, Al Asmari M, Islam A, Kapoor A, Briese T, Daszak P, Al Rabeeah AA, Lipkin WI. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerging Infectious Diseases. 2013;19(11):1819–1823. [PMC free article: PMC3837665] [PubMed: 24206838]

Nolan T, Roy-Ghanta S, Montellano M, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E, Kerdpanich A, Safadi MA, Cruz-Valdez A, Litao S, Lim FS, de Los Santos AM, Weber MA, Tinoco JC, Mezerville MH, Faingezicht I, Kosuwon P, Lopez P, Borja-Tabora C, Li P, Durviaux S, Fries L, Dubin G, Breuer T, Innis BL, Vaughn DW. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. Journal of Infectious Diseases. 2014;210(4):545–557. [PMC free article: PMC4111912] [PubMed: 24652494]

Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet Infectious Diseases. 2012;12(1):36–44. [PubMed: 22032844]

PCAST (President's Council of Advisors on Science and Technology). Report to the president on reengineering the influenza vaccine production enterprise to meet the challenges of pandemic influenza. 2010. [June 30, 2015]. https://www​.whitehouse​.gov/sites/default​/files/microsites/ostp​/PCAST-Influenza-Vaccinology-Report​.pdf.

Porter ME, Kramer MR. Creating Shared Value. Harvard Business Review. 2011;(January-February issue) [June 30, 2015]; https://hbr​.org/2011​/01/the-big-idea-creating-shared-value.

Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, Sealfon RS, Kanneh L, Moigboi A, Momoh M, Fullah M, Moses LM, Brown BL, Andersen KG, Winnicki S, Schaffner SF, Park DJ, Yozwiak NL, Jiang PP, Kargbo D, Jalloh S, Fonnie M, Sinnah V, French I, Kovoma A, Kamara FK, Tucker V, Konuwa E, Sellu J, Mustapha I, Foday M, Yillah M, Kanneh F, Saffa S, Massally JL, Boisen ML, Branco LM, Vandi MA, Grant DS, Happi C, Gevao SM, Fletcher TE, Fowler RA, Bausch DG, Sabeti PC, Khan SH, Garry RF. KGH Lassa Fever Program; Viral Hemorrhagic Fever Consortium; WHO Clinical Response Team. Clinical illness and outcomes in patients with Ebola in Sierra Leone. New England Journal of Medicine. 2014;371(22):2092–2100. [PMC free article: PMC4318555] [PubMed: 25353969]

Sertkaya A, Eyraud J, Birkenbach A, Franz C, Ackerley N, Overton V, Outterson K. Analytical framework for examining the value of antibacterial products. 2014. [June 30, 2015]. http://aspe​.hhs.gov/sp​/reports/2014/antibacterials​/rpt_antibacterials.cfm.

Sharma P, Towse A. New drugs to tackle antimicrobial resistance: Analysis of EU policy options. 2011. [June 30, 2015]. https://www​.ohe.org/publications​/new-drugs-tackle-antimicrobial-resistance-analysis-eu-policy-options.

Spellberg B, Sharma P, Rex JH. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nature Reviews Drug Discovery. 2012;11(2):168. [PMC free article: PMC3883457] [PubMed: 22293569]

Trock SC, Burke SA, Cox NJ. Development of an influenza virologic risk assessment tool. Avian Diseases. 2012;56(4 Suppl):1058–1061. [PubMed: 23402136]